By Kuda Pembere With Zimbabwe being among the 18 top-priority recipients of lenacapavir an HIV preventive drug pending local medicines regulatory approvals, Gilead Sciences, the principal maker has granted a non-exclusive license to leading India headquartered pharmaceutical manufacturer Hetero Group of Companies to manufacture and supply the drug. Gilead’s decision comes following much advocacy by AVAC to give non-exclusive licenses for the manufacturing of lenapavir. The partnership will broaden access to this novel HIV treatment usable in combination with other antiretrovirals while supporting efforts to prevent HIV through pre-exposure prophylaxis…
Read MoreZim among top priority lenacapavir recipients as Gilead licenses Hetero
